PMID- 26455778
OWN - NLM
STAT- MEDLINE
DCOM- 20160929
LR  - 20151130
IS  - 1166-7087 (Print)
IS  - 1166-7087 (Linking)
VI  - 25
IP  - 16
DP  - 2015 Dec
TI  - [Prostate cancer treated with androgen deprivation therapy: Care and monitoring 
      in daily practice].
PG  - 1132-9
LID - S1166-7087(15)00239-0 [pii]
LID - 10.1016/j.purol.2015.08.004 [doi]
AB  - OBJECTIVE: Our purpose was to identify measures implemented by urologists and 
      radiation oncologists at the initiation of a 6-month formulation of luteinizing 
      hormone releasing hormone (LHRH) agonist in patients with advanced PCa. MATERIAL: 
      This cross-sectional cohort survey was conducted during 6 months. Participants 
      completed a questionnaire of 15 items on the first prescription of an androgen 
      deprivation therapy (ADT), the parameters prescribed for monitoring and 
      information provided to patients. RESULTS: The median age of the 1100 enrolled 
      patients was 75 years (range: 51-98 years); 245 patients (29.0%) were metastatic 
      and 411 (39.4%) had a Gleason score >/= 8. Prior to the treatment initiation, the 
      dosage of the total testosterone was not very often performed (4.8%). Associated 
      comorbidities such as arterial hypertension (53.6%) and hypercholesterolemia 
      (31.8%) did not constitute a barrier to the initiation of ADT, alone (60.5%) or 
      combined with anti-androgens (61%). According to the recommendations of the 
      French Association of Urology (AFU), fasting glycemia was required in 427 
      patients (41.1%), lipid profile in 380 (36.1%), a blood count in 219 (21.1%) and 
      bone densitometry in 111 (10.8%). The advice given to patients involved diet and 
      lifestyle rules (61%). The potential risks of adverse events (AEs) mentioned were 
      mainly hot flashes (95.5%). CONCLUSION: Some recommendations seem insufficiently 
      followed by the French specialists on information and monitoring procedures of 
      ADT, especially in the cardiovascular field.
CI  - Copyright (c) 2015 Elsevier Masson SAS. All rights reserved.
FAU - Hennequin, C
AU  - Hennequin C
AD  - Service de cancerologie et radiotherapie, hopital Saint-Louis, 75010 Paris, 
      France. Electronic address: christophe.hennequin2@aphp.fr.
FAU - Bruyere, F
AU  - Bruyere F
AD  - Service d'urologie, CHRU Bretonneau, Tours, France; PRES, universite 
      Val-de-Loire, 37000 Tours, France.
FAU - Sedefdjian, A
AU  - Sedefdjian A
AD  - Societe Evidence Based Communication, 92500 Rueil-Malmaison, France.
FAU - Bourouina, R
AU  - Bourouina R
AD  - Astellas Pharma S.A.S, 26 quai Michelet-CS 90067, 92309 Levallois-Perret cedex, 
      France.
FAU - Roupret, M
AU  - Roupret M
AD  - Service d'urologie, hopital Pitie-Salpetriere (Assistance publique-Hopitaux de 
      Paris), 83, boulevard de l'Hopital, 75013 Paris, France; Institut universitaire 
      de cancerologie, GRC5, oncotype-uro, universite Paris 6, 75005 Paris, France.
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
TT  - Cancer prostatique traite par suppression androgenique: prise en charge et suivi 
      en pratique quotidienne.
DEP - 20151009
PL  - France
TA  - Prog Urol
JT  - Progres en urologie : journal de l'Association francaise d'urologie et de la 
      Societe francaise d'urologie
JID - 9307844
RN  - 0 (Androgen Antagonists)
RN  - 33515-09-2 (Gonadotropin-Releasing Hormone)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Androgen Antagonists/*therapeutic use
MH  - Cross-Sectional Studies
MH  - Drug Monitoring
MH  - Gonadotropin-Releasing Hormone/*agonists
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prostatic Neoplasms/*drug therapy
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - Androgen deprivation therapy
OT  - Cancer de la prostate
OT  - Effets secondaires
OT  - Metastasis
OT  - Metastase
OT  - Prostate cancer
OT  - Recurrence
OT  - Recidive
OT  - Side effects
OT  - Suppression androgenique
OT  - Survie
OT  - Survival
EDAT- 2015/10/13 06:00
MHDA- 2016/09/30 06:00
CRDT- 2015/10/13 06:00
PHST- 2015/04/30 00:00 [received]
PHST- 2015/07/10 00:00 [revised]
PHST- 2015/08/04 00:00 [accepted]
PHST- 2015/10/13 06:00 [entrez]
PHST- 2015/10/13 06:00 [pubmed]
PHST- 2016/09/30 06:00 [medline]
AID - S1166-7087(15)00239-0 [pii]
AID - 10.1016/j.purol.2015.08.004 [doi]
PST - ppublish
SO  - Prog Urol. 2015 Dec;25(16):1132-9. doi: 10.1016/j.purol.2015.08.004. Epub 2015 
      Oct 9.